Aerovate Therapeutics Inc
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
(0.0% 1d) (-8.8% 1m) (29.0% 1y) (0.0% 2d) (0.0% 3d) (-6.6% 7d) (24.46% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 601,776,000
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
treatment
add to watch list Paper trade email alert is off
Press-releases
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Published: 2024-03-27 (Crawled : 13:30) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: 6.78%
H: 7.19%
C: 4.05%
conference international trial therapeutics
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Published: 2024-03-25 (Crawled : 20:00) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: -1.48%
H: 2.91%
C: -3.39%
business therapeutics results
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
PEPG | $11.845 3.0% 3.36% 47K
|
|
| O: -2.65%
H: 4.17%
C: -4.82%
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: -2.08%
H: 7.76%
C: 6.73%
BPMC | News | $88.9 0.59% 0.58% 730K
|
Health Technology
|
| O: -0.75%
H: 3.12%
C: 1.55%
therapeutics
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: -1.79%
H: 3.93%
C: 1.75%
av-101 treatment hypertension trial therapeutics
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
Published: 2023-11-13 (Crawled : 15:30) - biospace.com/
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: -0.79%
H: 12.06%
C: 9.32%
business therapeutics financial results
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: -2.16%
H: 4.91%
C: -0.2%
business therapeutics results
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
Published: 2023-07-11 (Crawled : 21:00) - globenewswire.com
PEPG | $11.845 3.0% 3.36% 47K
|
|
| O: 1.88%
H: 3.23%
C: -1.96%
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: 1.67%
H: 2.3%
C: 0.77%
BPMC | News | $88.9 0.59% 0.58% 730K
|
Health Technology
|
| O: 1.32%
H: 1.0%
C: 0.95%
therapeutics
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
Published: 2023-06-01 (Crawled : 12:00) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: 0.06%
H: 6.52%
C: 3.26%
conference global therapeutics
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
Published: 2023-05-22 (Crawled : 17:00) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: 0.38%
H: 1.26%
C: -3.28%
av-101 conference international therapeutics
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Published: 2023-05-15 (Crawled : 20:00) - globenewswire.com
AVTE M | $21.6 -4.0% -4.17% 220K
|
Professional, Scientific, and T...
|
| O: -3.94%
H: 1.93%
C: -3.65%
business therapeutics results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Last 48 Hours Insiders Buying
ADMQ | $0.0532 -4.14% -40.18% 480K
|
|
10:30
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.41 1.34% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 930K
|
Electronic Technology
|
18:00
RMCF | $3.5501 0.57% 2.22% 18K
|
Consumer Non-Durables
|
20:10